

# Acid-Labile Cys-Protecting Groups for the Fmoc/*t*Bu Strategy: Filling the Gap


Miriam Góngora-Benítez,<sup>†,‡</sup> Lorena Mendive-Tapia,<sup>†,‡</sup> Iván Ramos-Tomillero,<sup>†,‡</sup>  
Arjen C. Breman,<sup>†</sup> Judit Tulla-Puche,<sup>\*,†,‡</sup> and Fernando Albericio<sup>\*,†,§,||</sup>

Institute for Research in Biomedicine, 08028-Barcelona, Spain, CIBER-BBN,  
08028-Barcelona, Spain, Department of Organic Chemistry, University of Barcelona,  
08028-Barcelona, Spain, and School of Chemistry, University of KwaZulu Natal,  
4001-Durban, South Africa

albericio@irbbarcelona.org; judit.tulla@irbbarcelona.org

Received September 16, 2012

## ABSTRACT



To address the existing gap in the current set of acid-labile Cys-protecting groups for the Fmoc/*t*Bu strategy, diverse Fmoc-Cys(PG)-OH derivatives were prepared and incorporated into a model tripeptide to study their stability against TFA. *S*-Dpm proved to be compatible with the commonly used *S*-Trt group and was applied for the regioselective construction of disulfide bonds.

Since the early days of peptide chemistry, the effective synthesis of natural or non-natural isomers, analogues, or *de novo* designed peptides with complex disulfide bridge patterns has been a demanding task. The oxidative folding<sup>1</sup> of fully deprotected linear peptides is a desirable and commonly applied approach for the synthesis of complex Cys-rich peptides. However, achievement of the desired disulfide bond connectivity through this approach is not always affordable. To overcome these challenging syntheses, a myriad of protecting groups for the  $\beta$ -thiol group of Cys, along with efficient regioselective protection schemes, have been developed.<sup>2</sup>

In recent years, several acid-labile Cys-protecting groups have been developed for the Fmoc/*t*Bu strategy (Figure 1).<sup>3</sup> Most of these are highly sensitive to acid, the *S*-Trt group being one of the most commonly used in the Fmoc/*t*Bu approach. In contrast, the *S*-Mob group requires a high TFA concentration and harsh conditions (high temperature and long reaction times) to be fully removed. In this regard, the current gap between *S*-Trt and *S*-Mob groups captured our attention and prompted us to browse through acid-labile protecting groups to find Cys-protecting groups that, ideally, could be quantitatively removable under mild acidic conditions and, simultaneously, show compatibility with *S*-Trt for their further application in synthetic strategies for the preparation of Cys-rich peptides. Thus, three distinct scaffolds, namely diphenylmethyl, biphenylmethyl, and benzyl groups, were selected and finely tuned for this purpose. Twelve Fmoc-Cys(PG)-OH (**1a–l**) were prepared and incorporated into the model tripeptide Fmoc-Ala-Cys(PG)-Leu-NH<sub>2</sub> (**2a–l**),

<sup>†</sup> Institute for Research in Biomedicine.

<sup>‡</sup> CIBER-BBN.


<sup>§</sup> University of Barcelona.

<sup>||</sup> University of KwaZulu Natal.

(1) (a) Moroder, L.; Besse, D.; Musiol, H. J.; Rudolph-Böhner, S.; Siedler, F. *Biopolymers (Pept. Sci.)* **1996**, *40*, 207. (b) Narayan, M.; Welker, E.; Wedemeyer, W. J.; Scheraga, H. A. *Acc. Chem. Res.* **2000**, *33*, 805. (c) Anfinsen, C. B. *Biochem. J.* **1972**, *128*, 737.

(2) (a) Barany, G.; Merrifield, R. B. Solid-phase peptide synthesis. In *The Peptides*; Gross, E., Meienhofer, J., Eds.; Academic Press: New York, 1979; Vol. 2, pp 1–84. (b) Andreu, D.; Albericio, F.; Solé, N. A.; Munson, M. C.; Ferrer, M.; Barany, G. In *Methods in Molecular Biology: Peptide Synthesis Protocols*; Pennington, M. W., Dunn, B. M., Eds.; Humana Press Inc.: Totowa, NJ, 1994; Vol. 35, pp 91–169.


(3) (a) Isidro-Llobet, A.; Álvarez, M.; Albericio, F. *Chem. Rev.* **2009**, *109*, 2455–2504. (b) Boulègue, C.; Musiol, H. J.; Prasad, V.; Moroder, L. *Chem. Today* **2006**, *24*, 24.



**Figure 1.** Acid-labile Cys-protecting groups for Fmoc/*t*Bu chemistry.

and their lability against TFA was studied and compared with the *S*-Mob group (**2m**) (Scheme 1).

**Scheme 1.** Preparation of Fmoc-Cys(PG)-OH Derivatives and Their Successive Incorporation into a Standard Tripeptide



After elongation on a Sieber amide resin, the standard tripeptides were cleaved from the resin and TFA-lability studies were carried out in solution with a range of reaction times and temperatures, in the presence of 2.5% TIS and 2.5% H<sub>2</sub>O as scavengers. The tripeptides were then analyzed by RP-HPLC to determine the percentage of deprotected Cys (Table 1).

As expected, the *S*-Mob protecting group was stable against diluted TFA treatments and required a high concentration of TFA, a longer reaction time, and an increase of temperature up to 40 °C to be totally removed (**2m**). Pleasantly, the diphenylmethyl (Dpm) group **1a**, along with two decorated benzyl moieties—**1h** with a *p*-methoxy and an *o*-methyl group and **1i** with two *o*-methoxy groups—exhibited the desired lability against TFA (**2a**, **2h–i**), while the others were not labile to TFA treatments (**2d–f**, **2j**) or were highly sensitive to TFA (**2b–c**, **2g**, **2k–l**). Furthermore, the three protecting groups **1a**, **1h**, and **1i** were stable under *S*-Trt cleavage conditions (10% TFA, **2a**, **2h–i**). This

**Table 1.** TFA-Lability Study of the Tripeptides **2**

	PG	TFA (%)	temp (°C)	reaction time	deprotected Cys (%)
<b>a</b>		10	25	5 min	0
		60	25	1 h	100
<b>b</b>		10	25	5 min	100
<b>c</b>		10	25	5 min	29
		20	25	30 min	100
<b>d</b>		10	25	5 min	0
		95	40	2 h	0
<b>e</b>		10	25	5 min	0
		95	40	2 h	0
<b>f</b>		10	25	5 min	0
		95	40	2 h	0
<b>g</b>		10	25	5 min	17
		20	25	30 min	100
<b>h</b>		10	25	5 min	0
		50	25	1 h	100
<b>i</b>		10	25	5 min	0
		50	25	1 h	100
<b>j</b>		10	25	5 min	0
		95	25	1 h	21
<b>k</b>		10	25	5 min	7
		20	25	30 min	100
<b>l</b>		10	25	5 min	9
		20	25	30 min	100
<b>m</b>		10	25	5 min	0
		95	40	2 h	100


outcome demonstrates the compatibility of these groups with *S*-Trt for regioselective disulfide construction.

Among the three promising protecting groups for Cys, the easily synthetically accessible *S*-Dpm was chosen as an alternative to the *S*-Mob group for advanced studies.<sup>4</sup>

(4) *S*-Mob and *S*-Dpm groups are not compatible. Under the cleavage conditions of *S*-Dpm, 22% *S*-Mob removal was observed.

Although *S*-Dpm was described as a Cys-protecting group by Photaki et al. back in 1970,<sup>5</sup> use of this group in Fmoc/*t*Bu chemistry has not been tackled until now.

### Scheme 2. Compatibility Study of Protecting Groups



Before further studies, the absence of racemization during Cys(Dpm) incorporation was proven (see Supporting Information (SI)). Next, the compatibility of *S*-Dpm with *S*-Trt and the highly sensitive acid-labile *S*-Mmt groups were thoroughly examined through a single experiment. Thus, a hexapeptide, which contained three Cys residues, was elongated onto a DKP<sub>handle</sub> linker, which allowed total free acid cleavage<sup>6</sup> (Scheme 2, hexapeptide **3**). After TFA treatment, the free thiol groups were methylated, and the Alloc group was then removed from the  $\alpha$ -N of the Lys residue, and the peptidyl-resin was treated with piperidine/THF to render the C-terminal DKP<sub>handle</sub>-protected hexapeptides (**3a–d**). At 10% TFA in the presence of 2.5% TIS as a scavenger, the *S*-Trt and *S*-Mmt groups were fully removed on solid phase. In contrast, *S*-Dpm was stable under these acidic conditions, requiring up to 90% TFA and 2.5% TIS for its entire removal (Table 2). It is worth mentioning that in any case the selective removal of *S*-Mmt vs *S*-Trt was not achieved, thereby showing the incompatibility of these protecting groups.<sup>7</sup>

After confirming the compatibility of *S*-Dpm with the *S*-Trt and *S*-Mmt groups, we were encouraged to apply the *S*-Dpm/*S*-Trt and *S*-Dpm/*S*-Mmt combinations in the protection scheme for the regioselective construction of intra- and intermolecular disulfide bridges. Thus, the regioselective syntheses of a double-chain bis-cystinyl

**Table 2.** Lability Study of the Acid-Labile *S*-Mmt, *S*-Trt, and *S*-Dpm Groups on Solid Phase<sup>a</sup>


TFA (%)	scavenger	reaction time	<b>3a</b> (%)	<b>3b</b> (%)	<b>3c</b> (%)	<b>3d</b> (%)
1	—	3 × 5 min	45	45	10	—
2	—	3 × 5 min	25	50	25	—
10	2.5% TIS	3 × 5 min	—	—	100	—
60	2.5% TIS	1 h	—	—	30	70
90	2.5% TIS	1 h	—	—	—	100

<sup>a</sup> All experiments were carried out with 15 mg of peptidyl-resin.

fragment 225–232/225'–232' of the human immunoglobulin G1 (IgG1)<sup>1a,8</sup> combining *S*-Mmt and *S*-Dpm, along with the preparation of the  $\alpha$ -conotoxin ImI<sup>9</sup> combining the *S*-Trt and *S*-Dpm groups, were carried out.

The hinge fragment of IgG1 was accomplished following two strategies in parallel (Scheme 3). In the first approach (Rink-amide resin), the *S*-Mmt group was selectively removed by diluted TFA treatments and the first disulfide bond was achieved by piperidine/DMF (1:4) on solid phase. The anchored *S*-Dpm-protected dimer **4** was then treated with TFA/TIS/H<sub>2</sub>O (95:2.5:2.5) for 1 h at 25 °C, and the resultant fully deprotected intermediate **7** was redissolved in DMSO/phosphate buffer (1:4) at pH 9 to render the final cyclic parallel dimer **8** (see SI).

### Scheme 3. Regioselective Syntheses of Hinge Fragment of IgG1 Combining *S*-Mmt and *S*-Dpm Protecting Groups<sup>a</sup>



<sup>a</sup> (i) TFA/TIS/CH<sub>2</sub>Cl<sub>2</sub> (5:2.5:92.5) (5 × 1 min); (ii) piperidine/DMF (1:4); (iii) H<sub>2</sub>O/ACN (1:9), 20% DMSO at pH 9; (iv) TFA/TIS/H<sub>2</sub>O (95:2.5:2.5) for 1 h at 25 °C; and (v) DMSO/phosphate buffer (1:4) at pH 9 and 25 °C.

In the second approach (Sieber-amide resin), the linear partial *S*-Dpm-protected peptide **5** was obtained by diluted TFA treatments. Subsequently, the first disulfide bond was accomplished in solution to render the protected dimer intermediate **6**. The second disulfide bridge was achieved as described before to render the bis-cystinyl parallel dimer **8** (Figure 2).


(9) (a) McIntosh, J. M.; Yoshikami, D.; Mahe, E.; Nielsen, D. B.; Rivier, J. E.; Gray, W. R.; Olivera, B. M. *J. Biol. Chem.* **1994**, *269*, 16733. (b) Nielsen, J. S.; Buczed, P.; Bulaj, G. *J. Pept. Sci.* **2004**, *10*, 249.

(5) Photaki, I.; Taylor-Papadimitriou, J.; Sakarellos, C.; Mazarakis, P.; Zervas, L. *J. Chem. Soc. (C)* **1970**, 2683.

(6) Góngora-Benítez, M.; Cristau, M.; Giraud, M.; Tulla-Puche, J.; Albericio, F. *Chem. Commun.* **2012**, *48*, 2313.

(7) Although it has been reported in the literature that *S*-Mmt can be selectively removed in the presence of *S*-Trt, actually it has no practical use because the safety window is so narrow that conditions should be carefully optimized and these are, therefore, not of general application.


(8) Wünsch, E.; Moroder, L.; Göhring-Romani, S.; Musiol, H.-J.; Göhring, W.; Bovermann, G. *Int. J. Peptide Protein Res.* **1988**, *32*, 268.



**Figure 2.** RP-HPLC analysis of the synthesized bis-cystinyl parallel dimer **8** from the Sieber-amide approach.


Although oxidative folding conditions can be carefully refined to provide a major isomer, the regioselective synthesis of the two-disulfide-containing  $\alpha$ -conotoxin family<sup>10</sup> members allows the correct construction of disulfide bond pattern present in their biologically active isomers to be ensured.<sup>9,11</sup> Thus, the  $\alpha$ -conotoxin ImI, a 12-mer peptide, which contains two disulfide bridges (2Cys-8Cys and 3Cys-12Cys), was prepared by combining two *S*-Dpm and two *S*-Trt for the protection of the Cys residues (Scheme 4). After completion of the peptide elongation

#### Scheme 4. Regioselective Synthesis of $\alpha$ -Conotoxin ImI Combining *S*-Trt and *S*-Dpm Protecting Groups



on a Sieber-amide resin, the partial *S*-Dpm-protected intermediate **9** was cleaved from the resin by diluted TFA treatments and the construction of the first disulfide bond was achieved in H<sub>2</sub>O/ACN (3:7) at pH 8 for 16 h at 25 °C, as determined by RP-HPLC analysis (see SI). At this

(10) (a) Myers, R. A.; Zafaralla, G. C.; Gray, W. R.; Abbott, J.; Cruz, L. J.; Olivera, B. M. *Biochemistry* **1991**, *30*, 9370. (b) Arias, H. R.; Blanton, M. P. *Int. J. Biochem. Cell Biol.* **2000**, *32*, 1017. (c) Janes, R. W. *Curr. Opin. Pharmacol.* **2005**, *5*, 280.



**Figure 3.** RP-HPLC analysis of the synthesized  $\alpha$ -conotoxin ImI **11** combining *S*-Dpm and *S*-Trt protecting groups.

point, various conditions were attempted to obtain the final bicyclic peptide. When the total deprotection and oxidation steps were performed consecutively, a mixture of two isomers was identified by RP-HPLC and RP-HPLC-ESMS analysis, while a single peak corresponding to the expecting isomer **11** was observed when the two steps were performed following a one-pot strategy (Figure 3).

In summary, the *S*-Dpm protecting group is an alternative to the *S*-Mob group. *S*-Dpm can be fully deblocked under the standard conditions used for cleavage and total deprotection steps in Fmoc chemistry, and it is fully compatible with two commonly used acid-labile protecting groups such as *S*-Trt and *S*-Mmt. Here we successfully applied *S*-Dpm for the regioselective synthesis of peptides containing intra- and intermolecular disulfide bonds. These results could be extrapolated to the other two protecting groups **1h** and **1i**.

**Acknowledgment.** The work has been partially financed by CICYT (CTQ2009-07758), the *Generalitat de Catalunya* (2009SGR 1024), the Institute for Research in Biomedicine Barcelona (IRB Barcelona), and the Barcelona Science Park. We thank Dr. Thomas Bruckdorfer from IRIS Biotech GmbH for fruitful discussions.

**Supporting Information Available.** Experimental procedures, compound characterization, RP-HPLC analyses, and spectral data of the Fmoc-Cys(PG)-OH derivatives. This material is available free of charge via the Internet at <http://pubs.acs.org>.

(11) (a) Walewska, A.; Bulaj, G. Mechanisms of the Oxidative Folding of Small, Disulfide-Rich Peptides. In *Oxidative Folding of Proteins and Peptides*; Moroder, L., Ed.; Royal Chemical Society: Cambridge, U.K., 2008. (b) Bulaj, G.; Olivera, B. M. *Antioxid. Redox Signal.* **2008**, *10*, 141.

The authors declare no competing financial interest.